PORTLAND, Ore. – A new scientific discovery may provide a future avenue for treatment and prevention of Alzheimer's disease.
A study published Nov. 28 in the journal JAMA Neurology examined aquaporin-4, a type of membrane protein in the brain. Using brains donated for scientific research, researchers at OHSU discovered a correlation between the prevalence of aquaporin-4 among older people who did not suffer from Alzheimer's as compared to those who had the disease.
"It suggests that aquaporin-4 might be a useful target in preventing and treating Alzheimer's disease," said senior author Jeffrey Iliff, Ph.D., an Assistant Professor in the Department of Anesthesiology and Perioperative Medicine in the OHSU School of Medicine. "However, we aren't under any illusion that if we could just fix this one thing, then we'd be able to cure Alzheimer's Disease."
Alzheimer's is a progressive disease, most often associated with aging, that causes problems with memory, thinking and behavior. It is the leading cause of dementia worldwide and is currently the sixth leading cause of death in the United States. The disease has no known cure but there are treatments available for some of its symptoms.
Aquaporin-4 is a key part of a brain-wide network of channels, collectively known as the glymphatic system, that permits cerebral-spinal fluid from outside the brain to wash away proteins such as amyloid and tau that build up within the brain. These proteins tend to accumulate in the brains of some people suffering from Alzheimer's, which may play a role in destroying nerve cells in the brain over time.
"This system, and the failure of the system, may be one of many things that goes wrong in people with Alzheimer's disease," Iliff said.
The study closely examined 79 brains donated through the Oregon Brain Bank, a part of the OHSU Layton Aging and Alzheimer's Disease Center. They were separated into three groups: People younger than 60 without a history of neurological disease; people older than 60 with a history of Alzheimer's; and people older than 60 without Alzheimer's.
Researchers found that in the brains of younger people and older people without Alzheimer's, the aquaporin-4 protein was well organized, lining the blood vessels of the brain. However within the brains of people with Alzheimer's, the aquaporin-4 protein appeared disorganized, which may reflect an inability of these brains to efficiently clear away wastes like amyloid beta. The study concluded that future research focusing on aquaporin-4 – either through its form or function – may ultimately lead to medication to treat or prevent Alzheimer's disease.
In 2015, a multidisciplinary team of scientists from OHSU led by Iliff was awarded a $1.4 million grant from the Paul G. Allen Family Foundation to use to develop new imaging techniques based on MRI to see these processes at work in the aging human brain for the first time.
In addition to Iliff, co-authors included Douglas M. Zeppenfeld; Matthew Simon, J. Douglas Haswell, and Daryl D'Abreo of the OHSU Department of Anesthesiology and Perioperative Medicine; Charles Murchison, Joseph F. Quinn, M.D., and Jeffrey Kaye, M.D., of the OHSU Department of Neurology; and Marjorie R. Grafe, M.D., Ph.D., and Randall L. Woltjer, M.D., Ph.D., of the Department of Pathology.
This work was supported by funding from the American Heart Association, grant 12SDG11820014, the Oregon Partnership for Alzheimer's Research, grants from the Research and Development Office of the Department of Veterans Affairs and the National Institutes of Health (NS089709), including Alzheimer's Disease Center grant AG08017 from the National Institute on Aging that supported the longitudinal follow-up and subsequent brain autopsies providing the human brain samples used in this study.
Oregon Health & Science University is a nationally prominent research university and Oregon's only public academic health center. It serves patients throughout the region with a Level 1 trauma center and nationally recognized Doernbecher Children's Hospital. OHSU operates dental, medical, nursing and pharmacy schools that rank high both in research funding and in meeting the university's social mission. OHSU's Knight Cancer Institute helped pioneer personalized medicine through a discovery that identified how to shut down cells that enable cancer to grow without harming healthy ones. OHSU Brain Institute scientists are nationally recognized for discoveries that have led to a better understanding of Alzheimer's disease and new treatments for Parkinson's disease, multiple sclerosis and stroke. OHSU's Casey Eye Institute is a global leader in ophthalmic imaging, and in clinical trials related to eye disease.
Story Source: Materials provided by Scienmag